NeuroSense provides Q3 update

NeuroSense provided an update from its CEO, Alon Ben-Noon, on the company’s clinical and operational developments during and immediately following Q3. The company’s amyotrophic lateral sclerosis – ALS – Phase 2b PARADIGM trial of PrimeC is expected to report clinical topline results in Q4, and a Phase 2 Alzheimer’s disease study is expected to enroll the first patient in the next several weeks. PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing induced pluripotent stem cells – iPSCs – generated from people living with ALS. In another independent study, PrimeC performed among the best in improving motor neuron survival when compared to several other ALS drugs in development and two ALS FDA approved drugs. NueroSense received Small and Medium-Sized Enterprise status from the EMA & opened office in Germany. SME status offers regulatory guidance and engagement in dialogue with EMA. The company is fully funded into Q2 2024 beyond clinical Phase 2b ALS results expected Q4 2023.